Harrow completes TYRVAYA acquisition, adds FDA-approved nasal spray for dry eye
Harrow Health closed its acquisition of TYRVAYA, an FDA-approved nasal spray for dry eye disease, expanding its ocular surface portfolio with a differentiated drop-free treatment option.
How Oyticker scores a story: impact and confidence describe the information, not a probability that a price moves.
What happened
Harrow Health announced completion of its acquisition of TYRVAYA on 5 October 2026. TYRVAYA is described as the first and only FDA-approved nasal spray for dry eye disease.
Why it matters
The acquisition adds a novel, non-drop formulation to Harrow's ocular franchise, potentially capturing market share from traditional eye-drop competitors and addressing patient compliance/convenience preferences. Dry eye disease is a large, growing market; a differentiated delivery mechanism may command pricing power and reduce competitive pressure from generic drops.
Market transmission
First-order: revenue accretion from TYRVAYA sales and potential margin expansion if priced above traditional drops. Second-order: improved portfolio diversification in ophthalmology reduces reliance on commodity eye-drop categories; potential for cross-selling synergies within Harrow's existing ocular customer base; valuation multiple re-rating if acquisition demonstrates successful integration and market adoption.
What to watch
TYRVAYA sales trajectory post-close; gross margins and operating leverage; management guidance on revenue contribution and synergy realization; competitive response from drop-based dry eye treatments; patient adoption rates and insurance coverage decisions.
Source:GlobeNewswire US
Oyticker provides market information and analysis for educational purposes. It is not investment advice: you remain responsible for your own decisions.